Next Generation Sequencing for the Prediction of the Antibiotic Resistance in <i>Helicobacter pylori</i>: A Literature Review

• Main Authors: Ilaria Maria Saracino (Author), Matteo Pavoni (Author), Angelo Zullo (Author), Giulia Fiorini (Author), Tiziana Lazzarotto (Author), Claudio Borghi (Author), Dino Vaira (Author)
• Format: Book
• Published: MDPI AG, 2021-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 10.3390/antibiotics10040437; 2079-6382
• Keywords: <i>H. pylori</i> antibiotic-resistance; molecular methods; nxt generation sequencing; whole genome sequencing; Therapeutics. Pharmacology; RM1-950
• Source: Antibiotics, Vol 10, Iss 4, p 437 (2021)

<b>Background and aims</b>: Only a few antimicrobials are effective against <i>H. pylori</i>, and antibiotic resistance is an increasing problem for eradication therapies. In 2017, the World Health Organization categorized clarithromycin resistant <i>H. pylori</i> as a "high-priority" bacterium. Standard antimicrobial susceptibility testing can be used to prescribe appropriate therapies but is currently recommended only after the second therapeutic failure. <i>H. pylori</i> is, in fact, a "fastidious" microorganism; culture methods are time-consuming and technically challenging. The advent of molecular biology techniques has enabled the identification of molecular mechanisms underlying the observed phenotypic resistance to antibiotics in <i>H. pylori</i>. The aim of this literature review is to summarize the results of original articles published in the last ten years, regarding the use of Next Generation Sequencing, in particular of the whole genome, to predict the antibiotic resistance in <i>H. pylori.</i><b>Methods</b>: a literature research was made on PubMed. The research was focused on II and III generation sequencing of the whole <i>H. pylori</i> genome. <b>Results</b>: Next Generation Sequencing enabled the detection of novel, rare and complex resistance mechanisms. The prediction of resistance to clarithromycin, levofloxacin and amoxicillin is accurate; for other antimicrobials, such as metronidazole, rifabutin and tetracycline, potential genetic determinants of the resistant status need further investigation.